Eprosartan
- Generic Name
- Eprosartan
- Brand Names
- Teveten HCT
- Drug Type
- Small Molecule
- Chemical Formula
- C23H24N2O4S
- CAS Number
- 133040-01-4
- Unique Ingredient Identifier
- 2KH13Z0S0Y
- Background
Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced.
- Indication
For the management of hypertension alone or in combination with other classes of antihypertensive agents. Also used as a first-line agent in the treatment of diabetic nephropathy, as well as a second-line agent in the treatment of congestive heart failure (only in those intolerant of ACE inhibitors).
- Associated Conditions
- Congestive Heart Failure (CHF), Diabetic Nephropathy, Hypertension
- Associated Therapies
- -
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 341
- Registration Number
- NCT04606563
- Locations
- 🇨🇦
Royal Jubilee Hospital, Nanaimo, British Columbia, Canada
🇨🇦St Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Abbott
- Target Recruit Count
- 665
- Registration Number
- NCT01631227
- Locations
- 🇩🇪
Site Reference ID/Investigator# 74066, Bochum, Germany
🇩🇪Site Reference ID/Investigator# 74065, Dresden, Germany
🇩🇪Site Reference ID/Investigator# 74062, Berlin, Germany
Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 24
- Registration Number
- NCT01087749
- Locations
- 🇺🇸
Clinical Reserach Center, UCSF, San Francisco,, California, United States
The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension
- Conditions
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2008-05-09
- Lead Sponsor
- Regional Hospital Holstebro
- Target Recruit Count
- 18
- Registration Number
- NCT00438945
- Locations
- 🇩🇰
Department of Medical Research, Holstebro Hospital, Holstebro, Denmark
The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans.
- Conditions
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2007-09-14
- Lead Sponsor
- Regional Hospital Holstebro
- Target Recruit Count
- 18
- Registration Number
- NCT00409903
- Locations
- 🇩🇰
Department of Medical Research, Holstebro Hospital, Holstebro, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.